354 Stock Chart & Stats
€22.20
-€0.20(-0.64%)
At close: 4:00 PM EDT
€22.20
-€0.20(-0.64%)
Day’s Range― - ―
52-Week Range€18.50 - €42.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€691.46M
Enterprise Value€2.24B
Total Cash (Recent Filing)€129.47M
Total Debt (Recent Filing)€857.79M
Price to Earnings (P/E)15.6
Beta0.75
Next Earnings
Nov 05, 2026EPS Estimate
1.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.53
Shares Outstanding32,555,614
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-3.13
Price to Book (P/B)4.87
Price to Sales (P/S)1.88
P/FCF Ratio4.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€43.61Price Target Upside96.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)6.64
Revenue Forecast (FY)€741.76M
Bulls Say, Bears Say
Bulls Say
ADHD Portfolio GrowthRapid Jornay PM growth and expanding branded market share indicate durable commercial traction in ADHD treatment. Rising prescriptions, prescriber reach, and share support a growing franchise that can diversify Collegium beyond its pressured opioid portfolio over the next several quarters.
Azstarys ExpansionThe Azstarys acquisition adds a complementary ADHD product with early revenue contribution, raised guidance, and stated intellectual-property protection through 2037. Collegium has also expanded its sales force, supporting a potentially durable platform for further prescription and revenue growth.
Cash GenerationStrong operating and free cash flow provide internal funding for debt reduction, commercial investment, and selective acquisitions. The close relationship between free cash flow and net income also indicates that recent profitability is materially supported by cash generation rather than relying primarily on accounting adjustments.
Bears Say
Elevated LeverageDebt remains large relative to equity, leaving Collegium more sensitive to earnings volatility and refinancing conditions. Although leverage improved from prior years, the balance sheet still limits financial flexibility after the Azstarys acquisition and could constrain future capital allocation if performance weakens.
Pain Portfolio PressureDeclines across NUCYNTA and Xtampza ER expose Collegium to sustained pressure in its legacy pain franchise. Authorized-generic pricing reduces net realizations, while lower Xtampza revenue can weaken the portfolio’s contribution and place greater dependence on successful ADHD execution.
Belbuca Loss-of-Exclusivity RiskA potential Belbuca generic launch in January 2027 creates a durable near-term risk to one of the pain portfolio’s stronger products. Generic entry could reduce pricing and volume, pressuring revenue and cash generation while increasing the importance of ADHD products as replacement growth drivers.
Collegium Pharmaceutical News
354 FAQ
What was Collegium Pharmaceutical’s price range in the past 12 months?
Collegium Pharmaceutical lowest stock price was €18.50 and its highest was €42.00 in the past 12 months.
What is Collegium Pharmaceutical’s market cap?
Collegium Pharmaceutical’s market cap is €691.46M.
When is Collegium Pharmaceutical’s upcoming earnings report date?
Collegium Pharmaceutical’s upcoming earnings report date is Nov 05, 2026 which is in 4 days.
How were Collegium Pharmaceutical’s earnings last quarter?
Collegium Pharmaceutical released its earnings results on Aug 06, 2026. The company reported €1.713 earnings per share for the quarter, beating the consensus estimate of €1.534 by €0.179.
Is Collegium Pharmaceutical overvalued?
According to Wall Street analysts Collegium Pharmaceutical’s price is currently Undervalued.
Does Collegium Pharmaceutical pay dividends?
Collegium Pharmaceutical does not currently pay dividends.
What is Collegium Pharmaceutical’s EPS estimate?
Collegium Pharmaceutical’s EPS estimate is 1.66.
How many shares outstanding does Collegium Pharmaceutical have?
Collegium Pharmaceutical has 32,555,614 shares outstanding.
What happened to Collegium Pharmaceutical’s price movement after its last earnings report?
Collegium Pharmaceutical reported an EPS of €1.713 in its last earnings report, beating expectations of €1.534. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Collegium Pharmaceutical?
Currently, no hedge funds are holding shares in DE:354
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Collegium Pharmaceutical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€43.61 (96.43% Upside)
€43.61 (96.43% Upside)
Blogger Sentiment
Bullish
DE:354 Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.23%
12-Months-Change
Fundamentals
Return on Equity
15.96%
Trailing 12-Months
Asset Growth
34.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Collegium Pharmaceutical
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
354 Company Deck
354 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong, accelerating growth in the ADHD franchise—Jornay PM momentum, the strategic Azstarys acquisition with early revenue and raised guidance, Belbuca growth and incremental formulary wins, and an 8% increase in adjusted EBITDA. Offsetting these positives were meaningful declines in the NUCYNTA franchise driven by authorized generic pricing, a decline in Xtampza ER, a GAAP net loss driven by acquisition-related costs, substantial cash deployed to acquire Azstarys and a modest leverage increase, and potential LOE risk for Belbuca. Overall, management presented a constructive outlook focused on ADHD-led growth and disciplined capital deployment while acknowledging near-term pain portfolio pressures and one-time acquisition impacts.View all DE:354 earnings summaries354 Stock 12 Month Forecast
Average Price Target
€43.61
▲(96.43% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Indivior
―
Amneal Pharmaceuticals
―
Aquestive Therapeutics
―